IN8bio progresses its novel approach to cancer therapy with gamma-delta T cell product candidates

IN8bio (NASDAQ:INAB) chief financial officer Patrick McCall takes Proactive’s Stephen Gunnion through the clinical-stage biopharmaceutical company’s novel approach to cancer therapy by advancing genetically modified gamma-delta T cells into the clinic using its DeltEx Platform.

McCall also provided updates on Phase 1 clinical trials on its lead candidates, INB-100 and INB-200, and revealed that IN8bio has partnered with the Dunbar CAR T-Cell Program at the University of Louisville as the manufacturing center for INB-400.

#ProactiveInvestors #IN8bio #DeltaEx #Nasdaq #cancertherapy